iRhythm Technologies Inc Corporate Analyst Meeting Transcript
Good morning, everyone. Welcome to iRhythm's 2022 Analyst/ Investor Day. I am Dan Wilson, EVP of Corporate Strategy for iRhythm, and I am honored to kick things off today. On behalf of the entire iRhythm team, we'd like to thank you all for joining us today, and we're excited to share our vision for the future of iRhythm.
Before we jump in, I want to remind everyone that this presentation will contain forward-looking statements. So the safe harbor here and risk factors apply. In addition, today's discussion will include references to adjusted EBITDA, which is a non-GAAP financial measure. Please refer to our latest SEC filings, including our 10-K and 10-Q for more information. We have an exciting agenda today. And you're going to hear from a number of leaders across our business. We will be running the day in 2 sessions.
In the first session, we will cover our overarching strategy for value creation, our focus on clinical led innovation, our growth strategies for our core U.S. business and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |